Initiating at Hold: A Second Straight In-Year Cut Resets FY25 to ~$30, and Management Won't Touch 2026 — Visibility Is Too Poor to Catch a Knife Down 34% in a Year

Results vs. Consensus

Q2 2025 Scorecard

Year-Over-Year Comparisons

Quarter-Over-Quarter Comparisons

Note: managed-care earnings are seasonally front-loaded (Q1 is structurally the strongest quarter as the benefit ratio builds through the year), so a portion of the QoQ EPS decline is normal seasonality. The 250bps QoQ rise in the benefit ratio, however, is the part that is not seasonal — it is the cost-trend deterioration showing through.

Quality of Beat/Miss

• Revenue: The ~$1B revenue beat is low quality from a margin standpoint — it is driven by higher premium yields (i.e., the company charging more to cover the very cost trend that is pressuring it) plus the home-health and specialty-pharmacy acquisitions. Revenue growth here is a symptom of the cost problem being repriced, not a sign of demand strength.
• Margins: The 260bps YoY rise in the benefit ratio to 88.9% is the entire story, and it is concentrated in two lines — ACA and Medicaid. A favorable out-of-period value-based-care settlement partly offset it, so underlying deterioration is modestly worse than the headline ratio suggests. The 140bps of operating-expense-ratio improvement is real and management-controlled, but it cannot offset a 260bps medical-cost swing.
• EPS: Adjusted EPS of $8.84 is "clean" relative to expectations only because expectations had already collapsed. The $1.12 GAAP-to-adjusted bridge ($7.72 → $8.84) is primarily intangible amortization from acquisitions, which is consistent with prior quarters and not an aggressive add-back.

Segment Performance

Health Benefits — the margin is where the cut lives

Health Benefits grew operating revenue 12% to $41.6B on premium-yield catch-up, the past year's acquisitions, and Medicare Advantage membership growth, partially offset by Medicaid attrition. But operating gain fell to $1.6B as ACA and Medicaid medical costs ran ahead of rates. Within the membership base, Medicaid fell 3.3% to 8.7M as redetermination-driven disenrollment continued; total medical membership slipped ~200K sequentially to 45.6M, with management citing both Medicaid losses and lower ACA effectuation.

"The consolidated benefit expense ratio was 88.9%, an increase of 260 basis points year-over-year, driven by our ACA and Medicaid businesses, partially offset by a favorable out-of-period settlement with a value-based care provider." — Mark Kaye, CFO

Assessment: This is the segment carrying the entire reset. The mix problem is structural for now: the most acute, highest-cost members migrated from Medicaid into ACA, the relatively healthy left the exchanges, and rates lag the resulting acuity. Until 2026 repricing and Medicaid rate catch-up flow through, Health Benefits margin is the binding constraint on the whole enterprise.

Carelon — the part of the story that still compounds

Carelon was the bright spot: operating revenue up 36% to $18.1B and operating gain up 33% to $0.9B. CarelonRx grew operating revenue >20% as it scaled specialty assets and won larger clients; Carelon Services grew revenue >50% on CareBridge integration and risk-based expansion across dual-eligible and high-acuity Medicaid populations. Margins moderated modestly — a deliberate function of CareBridge's different margin profile and up-market investment, not a deterioration.

"Carelon Services delivered greater than 50% growth in revenue and operating gain through its expansion of risk-based relationships and the integration of CareBridge." — Mark Kaye, CFO

Assessment: Carelon is the reason ELV is not simply a repricing-cycle health plan. The services flywheel — taking the company's own high-cost populations (oncology, behavioral, post-acute, LTSS) into downside-risk arrangements and selling the same capability externally — is exactly the lever management needs to "bend the trend" over a multi-year horizon. It is real and growing; it is just not large enough yet to offset a 260bps benefit-ratio swing in a single year.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management opened the call by naming the problem directly — Boudreaux led with "we know this adjustment is disappointing" rather than burying the cut — and the posture throughout was one of controlled, methodical accountability rather than defensiveness or spin. The notable tonal feature was the repeated insistence that the reset assumes no trend improvement and bets on no new initiatives, which reads as a deliberate effort to rebuild credibility after a second consecutive in-year cut. Where management was least convincing was on timing: on both the Medicaid rate-catch-up and the 2026 earnings bridge, the answers were directional and process-oriented, never quantified.

1. The Guidance Reset: Anatomy of the ~$30, and "Prudent, Not Bottoming"

The headline action is the cut from $34.15–$34.85 to ~$30. Management's framing was that this is a deliberately conservative reset that incorporates Q2's elevated trend and explicitly does not assume a second-half recovery. Boudreaux was emphatic that the company is "not betting on new initiatives to bend the trend or cost curve" within the 2025 number.

"This reset reflects the same pressures that others in the sector have now confirmed... this decision is anchored in our view that the elevated trends we are now observing will persist and reflects our updated visibility into the second half of the year. It is not based on assumptions of a near-term recovery. We are choosing to act now, not later." — Gail Boudreaux, CEO

Assessment: The "kitchen-sink, no-recovery-assumed" framing is the right way to reset, and if taken at face value it lowers the risk of a third cut. But the word "prudent" is doing a lot of work: the ~$30 still relies on an unquantified Q4 ACA surge assumption and a year-end discrete tax benefit, so it is not a pure trough number. We treat ~$30 as a credible but not bulletproof anchor.

2. ACA Morbidity: A Market-Wide Risk-Pool Problem, Not a Pricing Error

The single largest driver of the cut is the ACA exchange book, where the risk pool deteriorated as healthier, fully-subsidized members exited and higher-acuity members migrated in from Medicaid post-redetermination. Management was careful to frame this as a market-wide morbidity shift rather than an ELV-specific pricing or risk-adjustment miss, decomposing the ACA pressure as roughly 70% risk-pool acuity and 30% utilization (emergency room, behavioral health, specialty pharmacy) plus aggressive provider coding.

"You could think about the acuity in the ACA market at this point in time, largely being stabilized post those lower effectuation rates the industry saw in April." — Mark Kaye, CFO

One disclosed data point quantifies the severity: ELV's 2024–25 ACA cohort is utilizing the emergency room at nearly 2x the rate of its commercial-group members. Management also reiterated that its risk-adjustment (risk-transfer) assumptions are unchanged, because the deterioration is market-wide and its book is moving in line with the broader pool — not adversely selecting against it.

Assessment: The "market-wide, not us" framing is partly reassuring (no idiosyncratic mispricing) and partly worrying (the problem is not within ELV's unilateral control). The claim that acuity has "stabilized" is the most important — and least verifiable — assertion on the call. If true, ~$30 holds; if Q3 shows acuity still climbing, ~$30 is at risk.

3. Medicaid Rate-Acuity Lag: The "Couple of Rate Cycles" Problem

The second driver is Medicaid, where cost trend decelerated in Q2 but far less than expected, and acuity rose as lower-acuity members disenrolled under stricter eligibility reviews — mechanically raising the average cost of those who remain. Management characterized state rate discussions as "constructive," with the July cohort's rates landing in line with original assumptions; the problem is that those assumptions lagged the now-higher acuity.

"We do expect the full year 2025 Medicaid cost trend to be driven approximately 1/3 from acuity and about 2/3 from utilization and coding... different from 2024, where we indicated 60% was acuity, 40% was utilization." — Mark Kaye, CFO

Management expects Medicaid margins to still improve year-over-year in the back half and remain positive for the full year, albeit below long-term targets, with normalization "over a couple of rate cycles" as states incorporate fresher data.

Assessment: Medicaid is the more structurally tractable of the two problems — rates do catch up to acuity, it is a question of when, not whether — but "a couple of rate cycles" is 12–18 months of margin drag. The risk Wells Fargo flagged in Q&A is real: if forward trend keeps running ahead of base-period rate resets, the catch-up is a treadmill, not a finish line.

4. The Q4 ACA Utilization Surge — An Explicit Risk to the ~$30

Management embedded an unusually large Q4 ACA utilization assumption into the ~$30: if Congress lets the enhanced premium tax credits lapse at year-end, members are expected to pull elective care forward before out-of-pocket costs rise in 2026. Historically this "use-it-or-lose-it" effect is modest in the individual market, but the combination of higher prevailing acuity and a likely subsidy cliff led management to model a "much more meaningful Q4 surge than in prior years."

"If Congress allows the enhanced premium tax credits to lapse at the year-end, we will expect a measurable last-chance uptick in fourth quarter utilization as some members are going to schedule their elective care before their out-of-pocket costs rise in 2026... that's the key assumption that we've now embedded in our full year guidance outlook." — Mark Kaye, CFO

Assessment: This is the cleanest example of why ~$30 is not a pure floor. The Q4 surge is a genuine, sensible assumption, but its magnitude was never quantified, and management seasonality commentary (more earnings in Q3 than Q4) leans on it. If the surge runs hotter than modeled, Q4 disappoints even against the reset.

5. Medicare Advantage: The One Line Holding to Plan

Against two deteriorating lines, Medicare Advantage was the segment management could point to as in-line: trend remained elevated but consistent with expectations, Part D seasonality progressed as anticipated, and the company continues to target stable MA margins for the year. On 2026 bids, Norwood emphasized a disciplined, margin-first posture focused on HMO, dual-eligible, and retention-friendly geographies.

"It remained elevated, but it came in line with — consistently with our expectations. So similar to what we've been sharing in the first quarter... very much consistent, in line, so we didn't see any difference." — Gail Boudreaux, CEO, on MA trend

Assessment: MA being boringly in-line is genuinely valuable here — it is the segment where peers have stumbled badly, and ELV's multi-year discipline (bidding for margin over membership) is paying off. It is also the one place management's "we have this under control" narrative is currently backed by results rather than assertion.

6. Carelon: The Flywheel Keeps Spinning

Carelon's >30% revenue and operating-gain growth is the structural offset management is counting on over a multi-year horizon. The strategic logic is explicit: take ELV's own high-cost specialty populations (oncology, severe mental illness, MSK, post-acute, LTSS) into Carelon's downside-risk and care-management arrangements, improving both cost predictability and outcomes — and sell the same capability to external clients. More than one-third of benefit expense is now in downside-risk arrangements.

"These are not future state aspirations, they are embedded in our operations today and form the core of our multiyear plan to stabilize margins and build sustainable earnings power." — Gail Boudreaux, CEO

Assessment: Carelon is the franchise's most underappreciated asset in a quarter where it was almost entirely overshadowed by the benefit-ratio cut. It is the credible mechanism behind the "bend the trend" thesis. The investment case for ELV three years out is substantially a Carelon case; the investment case for the next 12 months is a Health Benefits margin case.

7. Provider Coding & IDR Abuse: The Lawsuit and the "Shift-Left" Response

Management spent meaningful airtime on what it characterized as aberrant provider billing — both AI-enabled upcoding by certain hospitals and, more pointedly, alleged abuse of the Independent Dispute Resolution (IDR) process under the No Surprises Act. ELV filed a legal suit against billing partners it says submitted thousands of disputes, sometimes hundreds in a single day, with payment requests inflated to as much as 21x billed charges.

"We've seen out-of-network providers and their billing partners submit thousands of disputes sometimes hundreds in a single day, and our payment request can be significantly inflated... sometimes those are from as much as 21x bill charges." — Gail Boudreaux, CEO

Assessment: This is partly a genuine cost driver and partly a narrative device — framing some of the trend as "abuse we are fighting" implies a recoverable component that pure morbidity does not. The "shift-left" analytics and payment-integrity push is credible and a real lever, but investors should not underwrite litigation outcomes or coding clawbacks into near-term numbers.

8. 2026 Setup: Repricing, the Subsidy Cliff, and the Policy Unknowns

Management would not give a 2026 number but did frame the levers: ACA products already repriced for higher acuity and potential subsidy expiration; Medicaid rates expected to catch up; MA bid for margin; and continued Carelon growth. The biggest acknowledged unknown is the disposition of the enhanced ACA subsidies — whether they expire, step down, or are renewed — plus the budget-reconciliation bill's Medicaid work requirements and more frequent eligibility reviews.

"The biggest unknown for us right now is the policy uncertainties around the ultimate disposition of the enhanced subsidies in the individual ACA market. Whether they expire or there's a step down... is really an important factor." — Gail Boudreaux, CEO

Assessment: The 2026 setup has a plausible bullish skeleton — repriced ACA into a smaller, higher-acuity but better-priced market; Medicaid rate catch-up; MA margin normalization — but every limb depends on a policy variable management cannot control. This is precisely why we are unwilling to underwrite the recovery today.

9. Capital Allocation: Buyback Paused for Flexibility, M&A Down-Shifted

ELV repurchased only ~$380M of stock in Q2 — a deliberately slowed pace — and emphasized preserving flexibility heading into a dynamic rate and margin environment. Management reaffirmed the long-term algorithm (≈50% of free cash flow to M&A/reinvestment, ≈30% to buybacks, ≈20% to dividends) and a full-year diluted share count target of 225–226M, but signaled 2025 M&A would be lighter as the focus shifts to integrating last year's acquisitions.

"With the stock trading well below what we see as its intrinsic value I really wanted to make sure that we retain full flexibility to be more opportunistic in the periods ahead." — Mark Kaye, CFO

Assessment: The slowed buyback is double-edged. The "intrinsic value" language is a confidence signal, but pulling back on repurchases while calling the stock cheap is in tension — it reads as prioritizing balance-sheet flexibility against an uncertain back half over conviction buying. We read it as prudence, but it is not the unambiguous "we're backing up the truck" signal a true-trough call would send.

Guidance & Outlook

Management framed the ~$30 as a "prudent foundation for execution" rather than a target to beat, embedding elevated trend persistence in both ACA and Medicaid through the second half and assuming no new cost initiatives bear fruit within the year. The benefit-expense-ratio guide of ~90% for the full year is the cleanest summary of the deterioration: from the 86.3% Q2 2024 comp, that is roughly 370bps of medical-cost pressure flowing through the P&L.

Implied second-half cadence: Management expects slightly more earnings in Q3 than Q4, an unusual skew driven by (1) the embedded Q4 ACA utilization surge and (2) a year-end discrete non-operating tax benefit and in-flight cost-management savings that partly cushion the Q4 step-down.

Street at: Consensus entering the print sat near $33.50 for FY2025; the ~$30 reset lands well below it and effectively forces the sell-side to re-baseline both 2025 and 2026.

Guidance style: Historically, ELV guided conservatively and beat; the last two years broke that pattern. The ~$30 is framed as a return to conservatism, but it must actually hold for two quarters before the market re-extends the company that benefit of the doubt.

Analyst Q&A Highlights

Decomposing the ACA pressure between unit cost and risk pool

The opening question pressed management to separate how much of the ACA deterioration is unit-cost trend versus risk-pool morbidity, and to reconcile the unchanged risk-adjustment assumption against visibly higher morbidity. Management's answer — ~70% acuity/morbidity, ~30% utilization and coding — became the analytical backbone for the rest of the call, and the reconciliation hinged on the claim that the morbidity shift is market-wide rather than ELV-specific.

Q: "Can you help delineate the pressure you're seeing in that business between unit cost trends and shifts in the risk pool? And... your expectation for risk adjustment this year remains unchanged for the current year. So can you explain how that's possible given the higher morbidity that we're seeing?"
— Andrew Mok, Barclays

A: "The first is the risk pool acuity and morbidity, which has risen materially... you could think about that as being about 70% of the total impact. Second and third impacts related to utilization... about 30%... On risk adjustment, the key point here is that the uptick in member acuity we are observing is driven by a broader market-wide morbidity trend, not by shift in our membership mix versus the market."
— Mark Kaye, CFO

Assessment: A clear, well-structured answer that did the work of locating the problem. The 70/30 decomposition and the "market-wide, our risk transfer is unchanged" logic are internally consistent — but they also concede that the larger (70%) piece is the one ELV cannot fix on its own.

Sizing the cut between ACA and Medicaid, and whether ACA margin recovery is even practical

A recurring line of questioning sought to size the relative contribution of ACA versus Medicaid to the reduction and to ask, pointedly, whether margin recovery on the exchanges is realistic at all given the need to absorb this year's deterioration plus the loss of enhanced subsidies. Management split the cut as "slightly more weighted towards ACA" and disclosed that the individual ACA operating margin is expected to decline year-over-year in the high-single-digit-percent range.

Q: "Can you size a little bit for us... how much the relative impact of each of those is in the guidance revision... And on the public exchanges, it sounds like you've got to reprice that... is margin recovery on the exchanges next year even practical to think about?"
— A.J. Rice, UBS

A: "If you think about the reduction in full year guidance split between ACA and Medicaid is slightly more weighted towards ACA... we do expect our operating margin on the individual ACA business to decline year-over-year in the high single-digit percent range. And that really underscores why we're proactively leaning into disciplined '26 pricing." — Mark Kaye, CFO

Assessment: The high-single-digit ACA margin decline is the most concrete sizing management offered, and it frames the 2026 ACA repricing as a margin-rebuild project, not a one-quarter fix. The honest subtext: the exchange business is currently running at or below breakeven.

Whether the Medicaid base-rate / forward-trend disconnect is structural

A skeptical line of questioning argued that ELV risks being perpetually underpaid in Medicaid — base-period rates set too low, then forward trend running ahead of resets — and asked whether that is an accurate characterization of the current dynamic. Management leaned on the "unusual post-pandemic cycle" framing and the constructiveness of state rate discussions, but conceded the data needs to catch up over multiple cycles.

Q: "The concern is kind of broadly that you're going to continue to get caught up on... base period rates being incorrectly set, but then there's going to be a disconnect... on forward trend where you're going to be continually underpaid. How do you think about that dynamic?"
— Stephen Baxter, Wells Fargo

A: "We're going through what I would call an unusual cycle coming out of the pandemic where there was significant redetermination, the acuity change pretty dramatically, and we have asked the states to move forward their view from their normal practices, and they've been very constructive... Our sense is that will normalize over a couple of rate cycles."
— Gail Boudreaux, CEO

Assessment: Management did not fully rebut the structural-underpayment thesis — it argued the disconnect is transitional and self-correcting over "a couple of rate cycles." That is plausible for the post-redetermination acuity bulge, but it does not address the forward-trend-vs-base-rate treadmill risk if utilization stays elevated. This is the open question we most want Q3 to answer.

The embedded Q4 ACA utilization surge and membership-attrition assumptions

A technical exchange probed what attrition and utilization assumptions underpin the back-half ACA outlook. Management disclosed that it assumes ACA membership stability through year-end but a larger-than-historical Q4 utilization "use-it-or-lose-it" surge tied to the potential subsidy lapse — the single most important swing factor inside the ~$30.

Q: "What assumptions are you making about the further attrition this year in the ACA enrollment base?"
— David Windley, Jefferies

A: "At least for the remainder of 2025, we've assumed membership stability in the ACA base. What we have done is think about what fourth quarter utilization is going to do... we will expect a measurable last chance uptick in fourth quarter utilization as some members are going to schedule their elective care before their out-of-pocket costs rise in 2026... we're going to see a much more meaningful Q4 surge than in prior years."
— Mark Kaye, CFO

Assessment: This exchange surfaced the load-bearing assumption in the guide. It is a reasonable behavioral prediction, but it is unquantified, and it means Q4 carries asymmetric downside: if the surge runs hot, even the reset is at risk.

Whether 2026 can grow above the 12% long-range EPS algorithm

An analyst asked directly whether the combination of ACA, Medicaid, and Medicare margin-recovery potential could let 2026 grow above the ~12% long-range plan, and for a framing of 2026 headwinds and tailwinds. Management declined to give a number but laid out the lever set, naming policy uncertainty around the enhanced subsidies as the dominant unknown.

Q: "Given the potential for margin improvement in Medicare, the exchanges and Medicaid next year, do you see the potential to grow above the 12% LRP next year? And maybe you could share your view of headwinds and tailwinds in 2026."
— Justin Lake, Wolfe Research

A: "We're really not in a position to give formal guidance, but let me sort of frame some of the areas... significant discipline in our pricing for cost trends... In Medicaid, we're also... working with other states... in Medicare Advantage... very disciplined benefit designs... The biggest unknown for us right now is the policy uncertainties around the ultimate disposition of the enhanced subsidies." — Gail Boudreaux, CEO

Assessment: Management's refusal to even directionally frame 2026 against the 12% LRP is the most important non-answer of the call. A management team confident in a clean recovery would have nudged expectations; the silence tells you the 2026 range is genuinely wide and policy-dependent.

Why believe Medicaid margins improve at all given the rate lag

The most pointed challenge of the call questioned why investors should model any Medicaid margin improvement over the next few years, given that the reconciliation bill threatens to create a fresh multi-year cycle of unprecedented risk-pool shifts on top of an unresolved rate-setting lag. Management reaffirmed conviction in Medicaid as a core franchise and pointed to improving state-actuary engagement and faster data sharing.

Q: "Why should we be assuming any improvement in Medicaid margins over the next couple of years if there seems to be this lag here between rate setting and the data coming in around where costs are real time?"
— Kevin Fischbeck, Bank of America

A: "We still think that both Medicaid and the ACA markets are both very positive markets... we are not passive in this relationship with the state... Their actuaries are now, I think, quite aware of the kind of shifts that occur when this enrollment changes... we do continue to think that these are core strategic franchises and that it's a short-term volatility issue that we're going to get through."
— Gail Boudreaux, CEO

Assessment: A conviction answer rather than an evidence answer. Management is asking investors to trust the state-partnership model and the data-sharing improvements; that trust is exactly what two consecutive cuts have eroded. The thesis is defensible, but it must now be proven, not asserted.

What They're NOT Saying

1. Any 2026 number — even a range or a direction. Management was repeatedly invited to frame 2026 against the 12% LRP and declined every time. For a company whose credibility rests on guidance, the refusal to offer even a directional 2026 anchor is the loudest omission of the call.
2. The magnitude of the Q4 ACA surge. The surge is the load-bearing assumption inside ~$30, yet its size was never quantified. "Much more meaningful than prior years" is a direction, not a number.
3. Individual-segment margins. Management explicitly does not break out ACA or Medicaid margins, leaving investors to triangulate from "high-single-digit ACA margin decline" and "Medicaid positive but below target." The opacity makes it hard to verify when the trough actually arrives.
4. Whether ~$30 is a floor. Management called it "prudent" and "a foundation," but never said it would not be cut again. After two straight in-year cuts, the absence of "this is the bottom" language is conspicuous.
5. Why the buyback slowed if the stock is "well below intrinsic value." The two statements coexisted without reconciliation. Preserving flexibility is reasonable, but management did not explain why conviction in undervaluation did not translate into more aggressive repurchase.

Market Reaction

• Pre-print setup: ELV closed at $344.55 on July 16, already down 6.6% YTD, down 8.2% over the trailing 30 days, and down a stark 33.9% over the trailing twelve months — the stock entered the print deep in a managed-care-wide de-rating, near the low end of a $336–$562 52-week closing range.
• Reaction-day move: The stock gapped down 3.1% at the open ($334.00) and sold off steadily through the session to close at $302.45, down 12.2% (−$42.10), on roughly 4.2x normal volume (7.4M vs. a 1.8M 30-day average). The S&P 500 closed +0.5% that day, so essentially the entire move was idiosyncratic.
• Where it sits: The $302.45 close took ELV to a fresh leg lower in its 52-week range and to roughly 10x the freshly-reset ~$30 FY25 adjusted EPS — a multiple that historically would have been reserved for a structurally impaired managed-care name, not a category leader.

The 12% single-session decline is best understood as a credibility re-rating, not just an earnings cut. A ~13% reduction in the EPS anchor mechanically argues for a ~13% price move; the fact that the stock fell roughly in line with the cut — rather than overshooting it — suggests the market is treating ~$30 as a genuine new baseline rather than pricing in a further cut. But the stock had already absorbed 34% of downside over the prior year, so this was a de-rating layered on a de-rating: the market is now valuing ELV as a "show me" story, and the burden of proof has shifted entirely onto the next two prints.

Street Perspective

Debate: Is ~$30 the trough, or a waystation to a lower number?

Bull view: The reset is deliberately conservative — no second-half recovery assumed, no new initiatives credited — so the bar is finally low enough to beat, and the next surprise is more likely to be a clear than a cut.

Bear view: ~$30 leans on an unquantified Q4 ACA surge and a discrete year-end tax benefit; with acuity still elevated and Medicaid rates lagging, a third cut cannot be ruled out, and management conspicuously refused to call it a floor.

Our take: The bull has the better of the framing but cannot yet prove it. The "no-recovery-assumed" reset genuinely lowers third-cut risk, but the Q4 surge assumption is a real asymmetry. We need one clean quarter — Q3 — to confirm ~$30 holds before treating it as the trough.

Debate: Is the ACA exchange business cyclically repricing or structurally impaired?

Bull view: This is a textbook market-wide repricing cycle: a smaller, higher-acuity exchange market in 2026, repriced for the new reality, with the marketplace-integrity rule and subsidy reset improving the risk pool — exactly the conditions under which disciplined carriers earn good margins on the other side.

Bear view: If enhanced subsidies expire, the exchange market shrinks and skews even sicker, and ELV's high-single-digit margin decline this year could prove to be the new normal rather than a cyclical low — a business that destroys value through the cycle.

Our take: Repricing cycles in managed care have historically resolved in favor of disciplined incumbents, and ELV's 2026 filings already capture the deterioration. We lean toward "cyclical, not structural" — but the policy variable (subsidy disposition) is large enough that we will not pay up for that view today.

Debate: Valuation — is ~10x a floor or a value trap?

Bull view: At ~10x a conservatively-reset $30, with a double-digit long-range EPS algorithm and a fast-growing Carelon embedded inside, ELV is simply too cheap; the de-rating has overshot, and patient capital is being paid to wait.

Bear view: A low multiple on a falling-and-uncertain earnings base is the definition of a value trap; until the E stops getting cut, the "cheap" multiple is illusory because the denominator is unstable.

Our take: Both are right, in sequence. The multiple is genuinely washed out and the Carelon optionality is real, but value only crystallizes once the earnings base is trusted. We are constructive on the eventual re-rate and unwilling to front-run it — which is precisely a Hold.

Model Update Needed

Valuation framework: We anchor to a fair-value range of roughly $300–$330, equivalent to ~10–11x a conservative ~$30 normalized adjusted EPS. Against the $302.45 close, the midpoint (~$315) implies only modest upside (~+4%), consistent with a Hold. The asymmetry is real on both sides: a clean Q3 that confirms ~$30 and a credible 2026 framework could re-rate the stock toward the low-to-mid-teens multiple it historically commanded (a path to $400+), while a third cut or a hot Q4 surge would re-open downside toward the high-$200s. We are unwilling to underwrite either tail until the trend stabilizes.

Thesis Scorecard Post-Earnings

Overall: Thesis initiated as balanced-but-cautious. The long-term franchise case (Carelon + scale + MA discipline) is intact and arguably underpriced; the near-term earnings case is genuinely impaired and not yet datable to a trough.

Action: Initiate at Hold. We want evidence of trend stabilization — not recovery — before moving to Outperform. A single clean quarter that confirms ~$30 and produces a credible 2026 framework would likely be enough to upgrade; a third cut would push us toward reassessing the structural-impairment tail.